Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

The program is examining the effectiveness of a protocol meant to ensure safety for pilots and air traffic controllers on ...

Pharmaceutical giant Pfizer is set to reduce its workforce in Ireland as it faces ongoing challenges in the wake of the COVID ...

The hormone replacement therapy market is witnessing substantial growth due to the rising occurrence of hormonal and targeted conditions such as menopause and osteoporosis, coupled with the ...

DelveInsight's Hormone Replacement Therapy Market Insights report provides the current and forecast market analysis, ...

WASHINGTON (Reuters) - U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they would expand coverage of Novo Nordisk's popular diabetes ...